Published in Hepatology on March 01, 2012
Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology (2015) 0.85
Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients. Radiother Oncol (2015) 0.83
Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. Liver Transpl (2013) 0.81
Noninvasive assessment of liver function. Curr Opin Gastroenterol (2015) 0.78
Fibrosis and cirrhosis in HCV infection. Gastroenterol Hepatol (N Y) (2014) 0.75
Analysis of the relationship between liver regeneration rate and blood levels. Pak J Med Sci (2015) 0.75
Functional imaging of radiation liver injury in a liver metastasis patient: imaging and pathologic correlation. J Gastrointest Oncol (2015) 0.75
Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res (2016) 0.75
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol (2016) 0.75
Shear wave elastography results correlate with liver fibrosis histology and liver function reserve. World J Gastroenterol (2016) 0.75
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C. Dig Dis Sci (2011) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Natural history of chronic hepatitis C. Hepatology (2002) 7.70
Liver biopsy. Hepatology (2009) 7.61
Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol (1986) 6.20
Global challenges in liver disease. Hepatology (2006) 4.55
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med (1993) 3.83
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology (2000) 3.49
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology (2008) 2.66
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol (2007) 2.34
Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther (2009) 2.11
Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J (2006) 2.11
Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int (2008) 2.09
Liver biopsy:complications and risk factors. World J Gastroenterol (1999) 1.91
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol (2006) 1.77
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2005) 1.63
The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology (2010) 1.56
Bleeding after liver biopsy. West J Med (1981) 1.50
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther (2006) 1.29
Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet (2006) 1.28
Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol (2003) 1.14
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut (2007) 1.08
Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol (1997) 1.01
Perfused Kupffer cell mass. Correlation with histology and severity of chronic liver disease. Dig Dis Sci (1995) 0.98
The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology (1995) 0.96
Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat (2009) 0.95
A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat (2008) 0.92
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther (2008) 0.91
The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther (2008) 0.87
Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther (2007) 0.84
Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin Transplant (2006) 0.84
Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit (1994) 0.83
Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock. Surgery (2009) 0.82
Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study. Eur J Gastroenterol Hepatol (2006) 0.82
The effect of age on plasma MEGX concentrations. Br J Clin Pharmacol (1997) 0.82
Noninvasive evaluation of liver disease severity. Clin Liver Dis (2006) 0.81
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Risk factors for incomplete bladder emptying after midurethral sling. Urology (2013) 2.76
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med (2003) 2.49
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology (2013) 2.03
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93